Literature DB >> 10531223

Lack of humoral immune protection against Treponema denticola virulence in a murine model.

L Kesavalu1, S C Holt, J L Ebersole.   

Abstract

This study investigated the characteristics of humoral immune responses to Treponema denticola following primary infection, reinfection, and active immunization, as well as immune protection in mice. Primary infection with T. denticola induced a significant (400-fold) serum immunoglobulin G (IgG) response compared to that in control uninfected mice. The IgG response to reinfection was 20, 000-fold higher than that for control mice and 10-fold higher than that for primary infection. Mice actively immunized with formalin-killed treponemes developed serum antibody levels seven- to eightfold greater than those in animals after primary infection. Nevertheless, mice with this acquired antibody following primary infection or active immunization demonstrated no significant alterations of lesion induction or decreased size of the abscesses following a challenge infection. Mice with primary infection developed increased levels of IgG3, IgG2b, and IgG2a antibodies, with IgG1 being lower than the other subclasses. Reinfected mice developed enhanced IgG2b, IgG2a, and IgG3 and less IgG1. In contrast, immunized mice developed higher IgG1 and lower IgG3 antibody responses to infection. These IgG subclass distributions indicate a stimulation of both Th1 and Th2 activities in development of the humoral immune response to infection and immunization. Our findings also demonstrated a broad antigen reactivity of the serum antibody, which was significantly increased with reinfection and active immunization. Furthermore, serum antibody was effective in vitro in immobilizing and clumping the bacteria but did not inhibit growth or passively prevent the treponemal infection. These observations suggest that humoral immune responses, as manifested by antibody levels, isotype, and antigenic specificity, were not capable of resolving a T. denticola infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531223      PMCID: PMC96949     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

Review 1.  Factors in virulence expression and their role in periodontal disease pathogenesis.

Authors:  S C Holt; T E Bramanti
Journal:  Crit Rev Oral Biol Med       Date:  1991

2.  HIV-associated periodontal disease: new oral spirochete found.

Authors:  D I Rosenstein; G R Riviere; K S Elott
Journal:  J Am Dent Assoc       Date:  1993-07       Impact factor: 3.634

3.  CD4+ Th2 T cells elicited by immunization confer protective immunity to experimental Borrelia burgdorferi infection.

Authors:  T D Rao; A Fischer; A B Frey
Journal:  Ann N Y Acad Sci       Date:  1994-08-15       Impact factor: 5.691

Review 4.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Treponema maltophilum sp. nov., a small oral spirochete isolated from human periodontal lesions.

Authors:  C Wyss; B K Choi; P Schüpbach; B Guggenheim; U B Göbel
Journal:  Int J Syst Bacteriol       Date:  1996-07

6.  Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3.

Authors:  S A Huber; B Pfaeffle
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  The outer membrane, not a coat of host proteins, limits antigenicity of virulent Treponema pallidum.

Authors:  D L Cox; P Chang; A W McDowall; J D Radolf
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Differential specific humoral response of susceptible and resistant mice infected with Mycobacterium lepraemurium.

Authors:  D M Martínez-Abraján
Journal:  Rev Latinoam Microbiol       Date:  1993 Apr-Jun

9.  Pathogen-related oral spirochetes from dental plaque are invasive.

Authors:  G R Riviere; K S Weisz; D F Adams; D D Thomas
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

10.  Porphyromonas gingivalis virulence in mice: induction of immunity to bacterial components.

Authors:  L Kesavalu; J L Ebersole; R L Machen; S C Holt
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more
  6 in total

1.  Omega-3 fatty acid effect on alveolar bone loss in rats.

Authors:  L Kesavalu; B Vasudevan; B Raghu; E Browning; D Dawson; J M Novak; M C Correll; M J Steffen; A Bhattacharya; G Fernandes; J L Ebersole
Journal:  J Dent Res       Date:  2006-07       Impact factor: 6.116

2.  Molecular characterization of Treponema denticola infection-induced bone and soft tissue transcriptional profiles.

Authors:  V Bakthavatchalu; A Meka; S Sathishkumar; M C Lopez; R K Verma; S M Wallet; I Bhattacharyya; B F Boyce; J J Mans; R J Lamont; H V Baker; J L Ebersole; L Kesavalu
Journal:  Mol Oral Microbiol       Date:  2010-08       Impact factor: 3.563

3.  Porphyromonas gingivalis and Treponema denticola Mixed Microbial Infection in a Rat Model of Periodontal Disease.

Authors:  Raj K Verma; Sunethra Rajapakse; Archana Meka; Clayton Hamrick; Sheela Pola; Indraneel Bhattacharyya; Madhu Nair; Shannon M Wallet; Ikramuddin Aukhil; Lakshmyya Kesavalu
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-05-31

4.  Lesion formation and antibody response induced by papillomatous digital dermatitis-associated spirochetes in a murine abscess model.

Authors:  Margaret K Elliott; David P Alt; Richard L Zuerner
Journal:  Infect Immun       Date:  2007-06-25       Impact factor: 3.441

5.  Immune response and alveolar bone resorption in a mouse model of Treponema denticola infection.

Authors:  Song F Lee; Elisoa Andrian; Elden Rowland; Ignacio Christian Marquez
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

6.  Characterization of Treponema denticola mutants defective in the major antigenic proteins, Msp and TmpC.

Authors:  Yuki Abiko; Keiji Nagano; Yasuo Yoshida; Fuminobu Yoshimura
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.